Azienda Ospedaliero-Universitaria Careggi (Aouc) | ClinicalTrials HQ

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms	Hemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, primary myelofibrosis	Active, not recruiting	Phase 1	2026-08-12		NCT06313593
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms	Hemic and Lymphatic Diseases, Myeloproliferative Disorders, blood coagulation disease, blood platelet disease, bone marrow disorder, essential thrombocythemia, hematologic disorder, hemorrhagic disease, primary myelofibrosis, thrombocytosis disease	Active, not recruiting	Phase 1	2026-08-10		NCT05936359
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)	Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Histologic Type, bone marrow disorder, hematologic disorder, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm	Active, not recruiting	Phase 2	2026-06-25		NCT04509700
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms	Disease Attributes, Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, blood coagulation disease, blood platelet disease, bone marrow disorder, essential thrombocythemia, hematologic disorder, hemorrhagic disease, myelodysplastic syndrome, myeloproliferative neoplasm, primary myelofibrosis, thrombocytosis disease	Active, not recruiting	Phase 1	2026-04-01		NCT04279847